抗糖尿病性チアゾリジンジオンの世界市場インサイト・予測(~2025年)

【英語タイトル】Global Antidiabetic Thiazolidinediones Market Insights, Forecast to 2025

QYResearchが出版した調査資料(QYR20FB11247)・商品コード:QYR20FB11247
・発行会社(調査会社):QYResearch
・発行日:2019年12月(※2024年版があります。お問い合わせください)
・ページ数:114
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートでは、世界の抗糖尿病性チアゾリジンジオン市場について調査・分析し、以下の構成でお届け致します。抗糖尿病性チアゾリジンジオンの種類別には、ロシグリタゾン、ピオグリタゾンに、用途別には、病院、診療所、その他に、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。

・調査販売
・エグゼクティブ・サマリー
・企業別抗糖尿病性チアゾリジンジオン売上データ
・地域別抗糖尿病性チアゾリジンジオン市場規模:北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他
・種類別抗糖尿病性チアゾリジンジオン市場規模:ロシグリタゾン、ピオグリタゾン
・用途別抗糖尿病性チアゾリジンジオン市場規模:病院、診療所、その他
・主要メーカーの企業情報:Sanofi、Takeda Pharmaceuticals、Eli Lilly、Merck & Co.、Novo Nordisk、Bristol-Myers Squibb、Pfizer、AstraZeneca、GlaxoSmithKline、Boehringer Ingelheim
・抗糖尿病性チアゾリジンジオンの市場規模予測
・バリューチェーン及び販売チャネル分析
・市場機会・課題・リスク・影響因子分析
...
【レポートの概要】

The global Antidiabetic Thiazolidinediones market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Antidiabetic Thiazolidinediones market based on company, product type, end user and key regions.
This report studies the global market size of Antidiabetic Thiazolidinediones in key regions like North America, Europe, China and Japan, focuses on the consumption of Antidiabetic Thiazolidinediones in these regions.
This research report categorizes the global Antidiabetic Thiazolidinediones market by top players/brands, region, type and end user. This report also studies the global Antidiabetic Thiazolidinediones market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sanofi
Takeda Pharmaceuticals
Eli Lilly
Merck & Co.
Novo Nordisk
Bristol-Myers Squibb
Pfizer
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim

Antidiabetic Thiazolidinediones market size by Type
Rosiglitazone
Pioglitazone

Antidiabetic Thiazolidinediones market size by Applications
Hospitals
Clinics
Other

Market size by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Central & South America
Brazil
Middle East & Africa
Turkey
GCC Countries
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Antidiabetic Thiazolidinediones market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Antidiabetic Thiazolidinediones market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Antidiabetic Thiazolidinediones companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Antidiabetic Thiazolidinediones submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Antidiabetic Thiazolidinediones are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Antidiabetic Thiazolidinediones market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Study Coverage
1.1 Antidiabetic Thiazolidinediones Product Introduction
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Antidiabetic Thiazolidinediones Market Size Growth Rate by Type
1.4.2 Rosiglitazone
1.4.3 Pioglitazone
1.5 Market by Application
1.5.1 Global Antidiabetic Thiazolidinediones Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Antidiabetic Thiazolidinediones Market Size
2.1.1 Global Antidiabetic Thiazolidinediones Revenue 2014-2025
2.1.2 Global Antidiabetic Thiazolidinediones Sales 2014-2025
2.2 Antidiabetic Thiazolidinediones Growth Rate by Regions
2.2.1 Global Antidiabetic Thiazolidinediones Sales by Regions
2.2.2 Global Antidiabetic Thiazolidinediones Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Antidiabetic Thiazolidinediones Sales by Manufacturers
3.1.1 Antidiabetic Thiazolidinediones Sales by Manufacturers
3.1.2 Antidiabetic Thiazolidinediones Sales Market Share by Manufacturers
3.2 Antidiabetic Thiazolidinediones Revenue by Manufacturers
3.2.1 Antidiabetic Thiazolidinediones Revenue by Manufacturers (2014-2019)
3.2.2 Antidiabetic Thiazolidinediones Revenue Share by Manufacturers (2014-2019)
3.3 Antidiabetic Thiazolidinediones Price by Manufacturers
3.4 Antidiabetic Thiazolidinediones Manufacturing Base Distribution, Product Types
3.4.1 Antidiabetic Thiazolidinediones Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Antidiabetic Thiazolidinediones Product Type
3.4.3 Date of International Manufacturers Enter into Antidiabetic Thiazolidinediones Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
4.1 Global Antidiabetic Thiazolidinediones Sales by Type
4.2 Global Antidiabetic Thiazolidinediones Revenue by Type
4.3 Antidiabetic Thiazolidinediones Price by Type

5 Breakdown Data by Application
5.1 Overview
5.2 Global Antidiabetic Thiazolidinediones Breakdown Data by Application

6 North America
6.1 North America Antidiabetic Thiazolidinediones by Country
6.1.1 North America Antidiabetic Thiazolidinediones Sales by Country
6.1.2 North America Antidiabetic Thiazolidinediones Revenue by Country
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Antidiabetic Thiazolidinediones by Type
6.3 North America Antidiabetic Thiazolidinediones by Application

7 Europe
7.1 Europe Antidiabetic Thiazolidinediones by Country
7.1.1 Europe Antidiabetic Thiazolidinediones Sales by Country
7.1.2 Europe Antidiabetic Thiazolidinediones Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Antidiabetic Thiazolidinediones by Type
7.3 Europe Antidiabetic Thiazolidinediones by Application

8 Asia Pacific
8.1 Asia Pacific Antidiabetic Thiazolidinediones by Region
8.1.1 Asia Pacific Antidiabetic Thiazolidinediones Sales by Region
8.1.2 Asia Pacific Antidiabetic Thiazolidinediones Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Thailand
8.1.10 Malaysia
8.1.11 Philippines
8.1.12 Vietnam
8.2 Asia Pacific Antidiabetic Thiazolidinediones by Type
8.3 Asia Pacific Antidiabetic Thiazolidinediones by Application

9 Central & South America
9.1 Central & South America Antidiabetic Thiazolidinediones by Country
9.1.1 Central & South America Antidiabetic Thiazolidinediones Sales by Country
9.1.2 Central & South America Antidiabetic Thiazolidinediones Revenue by Country
9.1.3 Brazil
9.2 Central & South America Antidiabetic Thiazolidinediones by Type
9.3 Central & South America Antidiabetic Thiazolidinediones by Application

10 Middle East and Africa
10.1 Middle East and Africa Antidiabetic Thiazolidinediones by Country
10.1.1 Middle East and Africa Antidiabetic Thiazolidinediones Sales by Country
10.1.2 Middle East and Africa Antidiabetic Thiazolidinediones Revenue by Country
10.1.3 Turkey
10.1.4 GCC Countries
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Antidiabetic Thiazolidinediones by Type
10.3 Middle East and Africa Antidiabetic Thiazolidinediones by Application

11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Company Business Overview
11.1.3 Sanofi Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Sanofi Antidiabetic Thiazolidinediones Products Offered
11.1.5 Sanofi Recent Development
11.2 Takeda Pharmaceuticals
11.2.1 Takeda Pharmaceuticals Company Details
11.2.2 Company Business Overview
11.2.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Products Offered
11.2.5 Takeda Pharmaceuticals Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Company Business Overview
11.3.3 Eli Lilly Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Eli Lilly Antidiabetic Thiazolidinediones Products Offered
11.3.5 Eli Lilly Recent Development
11.4 Merck & Co.
11.4.1 Merck & Co. Company Details
11.4.2 Company Business Overview
11.4.3 Merck & Co. Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Merck & Co. Antidiabetic Thiazolidinediones Products Offered
11.4.5 Merck & Co. Recent Development
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Details
11.5.2 Company Business Overview
11.5.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Novo Nordisk Antidiabetic Thiazolidinediones Products Offered
11.5.5 Novo Nordisk Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Company Business Overview
11.6.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Products Offered
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Company Business Overview
11.7.3 Pfizer Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Pfizer Antidiabetic Thiazolidinediones Products Offered
11.7.5 Pfizer Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 Company Business Overview
11.8.3 AstraZeneca Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.8.4 AstraZeneca Antidiabetic Thiazolidinediones Products Offered
11.8.5 AstraZeneca Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 Company Business Overview
11.9.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.9.4 GlaxoSmithKline Antidiabetic Thiazolidinediones Products Offered
11.9.5 GlaxoSmithKline Recent Development
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Details
11.10.2 Company Business Overview
11.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Boehringer Ingelheim Antidiabetic Thiazolidinediones Products Offered
11.10.5 Boehringer Ingelheim Recent Development

12 Future Forecast
12.1 Antidiabetic Thiazolidinediones Market Forecast by Regions
12.1.1 Global Antidiabetic Thiazolidinediones Sales Forecast by Regions 2019-2025
12.1.2 Global Antidiabetic Thiazolidinediones Revenue Forecast by Regions 2019-2025
12.2 Antidiabetic Thiazolidinediones Market Forecast by Type
12.2.1 Global Antidiabetic Thiazolidinediones Sales Forecast by Type 2019-2025
12.2.2 Global Antidiabetic Thiazolidinediones Revenue Forecast by Type 2019-2025
12.3 Antidiabetic Thiazolidinediones Market Forecast by Application
12.4 North America Antidiabetic Thiazolidinediones Forecast
12.5 Europe Antidiabetic Thiazolidinediones Forecast
12.6 Asia Pacific Antidiabetic Thiazolidinediones Forecast
12.7 Central & South America Antidiabetic Thiazolidinediones Forecast
12.8 Middle East and Africa Antidiabetic Thiazolidinediones Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Antidiabetic Thiazolidinediones Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer



【掲載企業】

Sanofi、Takeda Pharmaceuticals、Eli Lilly、Merck & Co.、Novo Nordisk、Bristol-Myers Squibb、Pfizer、AstraZeneca、GlaxoSmithKline、Boehringer Ingelheim

★調査レポート[抗糖尿病性チアゾリジンジオンの世界市場インサイト・予測(~2025年)] (コード:QYR20FB11247)販売に関する免責事項を必ずご確認ください。
★調査レポート[抗糖尿病性チアゾリジンジオンの世界市場インサイト・予測(~2025年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆